Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects
Authors:
Open Access
- 16 October 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 10, 1216102
Abstract
Glioma is one of the most intractable types of cancer, due to delayed diagnosis at advanced stages. The clinical symptoms of glioma are unclear and due to a variety of glioma subtypes, available low-invasive testing is not effective enough to be introduced into routine medical laboratory practice. Therefore, recent advances in the clinical diagnosis of glioma have focused on liquid biopsy approaches that utilize a wide range of techniques such as next-generation sequencing (NGS), droplet-digital polymerase chain reaction (ddPCR), and quantitative PCR (qPCR). Among all techniques, NGS is the most advantageous diagnostic method. Despite the rapid cheapening of NGS experiments, the cost of such diagnostics remains high. Moreover, high-throughput diagnostics are not appropriate for molecular profiling of gliomas since patients with gliomas exhibit only a few diagnostic markers. In this review, we highlighted all available assays for glioma diagnosing for main pathogenic glioma DNA sequence alterations. In the present study, we reviewed the possibility of integrating routine molecular methods into the diagnosis of gliomas. We state that the development of an affordable assay covering all glioma genetic aberrations could enable early detection and improve patient outcomes. Moreover, the development of such molecular diagnostic kits could potentially be a good alternative to expensive NGS-based approaches.Keywords
This publication has 191 references indexed in Scilit:
- EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180Oncogene, 2013
- K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomasActa Neuropathologica, 2012
- Detection of 1p19q Deletion by Real-Time Comparative Quantitative PCRBiomarker Insights, 2012
- EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathwayOncogene, 2011
- Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular MetabolismJNCI: Journal of the National Cancer Institute, 2010
- The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastomaActa Neuropathologica, 2010
- Familial risks in nervous-system tumours: a histology-specific analysis from Sweden and NorwayThe Lancet Oncology, 2009
- Next-generation DNA sequencingNature Biotechnology, 2008
- Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular DomainPLOS Medicine, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005